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Chronic internal inflammation secondary to adiposity is a risk factor for sporadic breast cancer and Post-Menopausal
Breast Cancer (PMBC) is largely defined as such. Adiposity is one of the clinical criteria for the diagnosis of Metabolic
Syndrome (MetS) and is a risk factor for PMBC. We examined SNPs of eight genes implicated in adiposity, inflammation
and cell proliferation in a Prospective-specimen-collection, Retrospective-Blinded-Evaluation (PRoBE) design approach.
A total of 180 cases and 732 age-matched controls were identified from the MyCode prospective biobank database
and then linked to the Clinical Decision Information System, an enterprise-wide data warehouse, to retrieve
clinico-demographic data. Samples were analyzed in a core laboratory where the personnel were masked to their
status. Results from multivariate logistic regression yielded one SNP (rs2922126) in the GHSR as protective against
PMBC among homozygotes for the minor allele (A/A) (OR = 0.4, 95% CI 0.18-.89, P-value = .02); homozygosity for
the minor allele (C/C) of the SNP (rs889312) of the gene MAP3K1 was associated with the risk of PMBC (OR = 2.41,
95% CI 1.25-4.63 P-value = .008). Advanced age was protective against PMBC (OR = 0.98, 95% CI 0.95-0.99, P-value = .02).
Family history of breast cancer (OR = 2.22, 95% CI 1.14-4.43. P = .02), HRT (OR = 3.35; 95% CI 2.15-5.21, P < .001),
and MetS (OR = 14.83, 95% CI 5.63-39.08, P < .001) and interaction between HRT and MetS (OR = 39.38, 95% CI
15.71-98.70, P < .001) were associated with the risk of PMBC. We did not detected significant interactions between
SNPs or between the SNPs and the clinico-demographic risk factors. Our study further confirms that MetS increases the
risk of PMBC and argues in favor of reducing exposure to HRT. Our findings are another confirmation that low penetrance
genes involved in the inflammatory pathway, i.e. MAP3KI gene, may have a plausible causative role in PMBC. Given the
fact that genetic constitutionality of individuals cannot be changed, efforts should be focused on life style modification.
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Post-menopausal breast cancer (PMBC) is largely defined
as a sporadic disease, as most women diagnosed with
PMBC do not have a first degree family history of breast
cancer. Of all identified modifiable risk factors for PMBC,
adiposity has been known to have the strongest (Risk ratio =
1.67) and the largest population attributable risk (>20%)* Correspondence: astark1@geisinger.edu
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in any medium, provided the original work is p(Sprague et al. 2008). Adipose tissue as an endocrine organ
is metabolically active and is involved in several biochem-
ical pathways; the association between adiposity and PMBC
most likely is not limited to one pathway or biochemical
mechanism, per se (Galic et al. 2010). In post-menopausal
women, peripheral adipose tissue is the primary source
of circulating estrogens which are synthesized from its
androgen precursors (Carmichael 2006; Gruber et al. 2002).
Extensive epidemiologic and clinical correlative studies
support that post-menopausal adiposity is associated with
elevated circulating levels of estradiol and estrone and
the risk of hormone positive breast cancer (Missmer et al.Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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Furthermore, chronic internal inflammation secondary
to adiposity has been associated with the risk of PMBC
(Aghamohammadzaeh and Heagerty 2012; Cowey and
Hardy 2006; Perez De Heredia et al. 2012). Results from
animal and translational clinical studies suggest of macro-
phage infiltration into mammary and subcutaneous ad-
ipocytes and formation of crown-like structures around
necrotic adipocyte which in turn activates the transcrip-
tion factor, nuclear factor kappa-light-chain-enhancer of
activated B cells (NF-κB) and induces pro-inflammatory
mediators such as tumor necrosis factor-α (TNF- α),
interleukines and cyclo-oxygenase-2 (COX-2) (Cowey and
Hardy 2006; Perez De Heredia et al. 2012; Morris et al.
2011). These pro-inflammatory factors activate cytochrome
P450 19 (CYP19) gene transcription yielding elevation
in aromatase gene activity. (Festa et al. 2001) In addition,
it has been proposed that chronic internal inflammation
lends to perpetual generation of reactive oxygen and ni-
trogen species which in turn promotes a variety of
damages ranging from mutations to post-translation mod-
ifications of proteins involved in apoptosis, DNA repair
and cell cycle check points (Festa et al. 2001; Pollard 2008;
Hamed et al. 2012; Hussain and Harris 2007).
Metabolic syndrome (MetS) is an amalgamation of several
clinical signs and symptoms of which a minimum of three
of the five risk factors, insulin resistance, hypertension,
hyperlipidemia and low serum levels of HDL cholesterol,
and obesity are required for diagnosis of this syndrome
(Grundy et al. 2004; Grundy 2005). Remarkably, research on
the association between MetS and PMBC is limited and
results are not conclusive (Aghamohammadzaeh and
Heagerty 2012; Bondia-Pons et al. 2012; Bjorge et al.
2010; Sinagra et al. 2002; Rosato et al. 2011; Kabat et al.
2009; Agnoli et al. 2010).
The natural history of breast cancer involves patho-
logically defined multi step process, starting from hyper-
plastic lesions to in situ and finally to invasive cancer,
over a period of time (Polyak 2007; Dupont and Page
1985; Hartman et al. 2005). It is well accepted that not
all women diagnosed with hyperplastic or in situ lesions
subsequently are diagnosed with invasive breast cancer;
nor all woman with the diagnosis of MetS eventually are
diagnosed with the disease. These observations suggest
that certain exogenous factors in conjunction with genetic
predisposition can alter host susceptibility to carcino-
genesis. In view of these observations, we conducted a
retrospective study with the objective of estimating the
association between MetS and PMBC; in addition, we
evaluated the potential association of variants (SNPs) of
eight genes which have been implicated in harboring sus-
ceptibility to adiposity, inflammation and cell proliferation
(Frayling et al. 2007; Kakamani et al. 2011; Hunter et al.
2007; Dossus et al. 2008; Langsenlehner et al. 2006;Zhang et al. 2012; Healey et al. 2011; Dossus et al. 2010;
Stacey et al. 2007; Andreasen et al. 2008; Rebbeck et al.
2009; Easton et al. 2007; Brasky et al. 2011).
Materials and methods
Study design
We implemented a prospective-specimen-collection,
retrospective-blinded-evaluation (PRoBE) design approach
(Pepe et al. 2008). We benefited from the MyCode pro-
spective cohort biobanking project where blood samples
are collected and procured from the primary care patient
population across 31 counties within Geisinger Health
System (GHS) service catchments. The banked samples
are representative of the primary care patient popula-
tion at GHS because of the high accrual rate of 89% of
patients approached. At the time of collection, blood
samples are processed according to the standard proto-
col, serum and DNA are then aliquoted into freezer
vials, and managed by a sample tracking software
FreezerWorks (Dataworks Development, Inc. Mountlake
Terrace, WA) before banking in the designated freezers.
All samples can be linked to various electronic databases
such as Clinical Decision Information System (CDIS). The
MyCode project is in full compliance with the U.S.
Congress Health Insurance Portability and Accountability
Act (HIPAA) of 1996 and has the approval of the Institu-
tional Review Board.
Case definition and identification
We defined cases as women with the diagnosis of breast
cancer between January 1, 2001 and December 31, 2010.
Cases were identified using the ICD-9 coding system
(174.x). The MyCode database was linked to medical
record numbers and subsequently to the electronic health re-
cords (EHR). Women whose diagnoses pre-dated 1/1/2001,
women with diagnosis of malignancies of other organs sites
except for squamous and/or basal cell carcinoma were
excluded, women with medical conditions that required
chronic intake of steroids and women younger than age
40 or older than 79 years were excluded.
Control selection
Members of the cohort with no history of breast or other
organ site malignancies or chronic prescription of steroids
comprised the control group. We applied a ratio of one
case to four controls, matched by age (± 5 years) and year
of entry into the cohort. Date of blood donation to the
MyCode prospective biobanking was considered the entry
point for each person into the cohort.
Data elements
Demographic and clinical data were retrieved from CDIS,
an enterprise-wide data warehouse. Data were downloaded
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Data quality control and assurance
We developed a standard operational procedure for man-
ual review of data from EHR. One of the study personnel
with training in medical abstraction reviewed the EHRs
over a period of nine months. The validity of electronic-
ally downloaded data was evaluated against the manually
reviewed and retrieved data (Feng et al. 2013).
Definition of metabolic syndrome
We used the World Health Organization (WHO) criteria
of 1999 to classify women with or without MetS.16 The
WHO criteria require presence of three clinically diagnosed
symptoms, the diagnosis of insulin resistance in combin-
ation with two other symptoms (Table 1). Women with
clinical documentation of type II diabetes, or impaired fast-
ing glucose or impaired glucose tolerance and any two of
the symptoms listed in Table 1 then were categorized into
the MetS group. Height and weight data were collected
from the first encounter with the health care system until
the date of diagnosis of breast cancer. For each woman, we
calculated her average value of weight and height that
were measured across all clinical visits. The average values
then were applied to calculate body mass index (BMI).
Selection of SNPs
In selecting the genes and their SNPs we reviewed
findings from GWAS and other independent studies and
applied minor allele frequency filtering approach and
function prediction method to select a total of 64 SNPs of
eight genes (Frayling et al. 2007; Kakamani et al. 2011;
Hunter et al. 2007; Dossus et al. 2008; Langsenlehner et al.
2006; Zhang et al. 2012; Healey et al. 2011; Dossus et al.
2010; Stacey et al. 2007; Andreasen et al. 2008; Rebbeck
et al. 2009; Easton et al. 2007; Brasky et al. 2011)
(Table 2).Table 1 Clinical criteria for metabolic syndrome
established by World Health Organization
Clinical diagnosis Indications
1. Insulin Resistance Adult onset/type II diabetes or
Impaired fasting glucose or
Impaired glucose tolerance or
2. Hypertension Antihypertensive medication or
Urinary excretion rate of ≥ 20μg/min or
Albumin:Creatinine ratio ≥ 30 mg/g
3. Hyperlipidemia Serum triglyceride ≥ 150 mg/dl
4. HDL cholesterol level Serum level < 39 mg/dl
5. Obesity Body Mass Index > 30 kg/m2 or
Waist:Hip ratio >0.85Laboratory analysis
Banked samples were retrieved and were sent to the core
laboratory for analysis. All samples were marked with
the study unique identifiers and the laboratory personnel
and the collaborating investigators remained masked to
the status of samples.
DNA isolation
DNA was extracted from EDTA-anticoagulated whole
blood using QIAsymphony SP Robot with Qiagen QIA-
symphony DNA Midi Kit (Qiagen, Valencia, California)
according to the manufacturer’s protocol. Quantification
of extracted DNA was performed using a NanoDrop
ND-1000 spectrophotometer (NanoDrop Technologies,
Wilmington, Delaware).
Genotype analysis
Single nucleotide polymorphism genotyping was performed
on TaqMan® OpenArray System with assay kit (64 assay
format) and Genotyping Master Mix purchased from Life
Technologies (Life Technologies, Foster City, California),
according to the manufacturer’s protocol. Briefly, 10 ul of
each DNA samples (containing 10 ng of DNA, 5 μL of
TaqMan Genotyping Master Mix, 0.25 μL of 40x assay
mix, and water) plated in 384 well plate were loaded on
OpenArray assay slide with Life Technologies OpenArray®
AccuFill™ System (Life Technologies, Foster City, California)
then performed PCR on GeneAmp PCR System 9700
(Life Technologies, Foster City, California) as follows:
93°C for 10 minutes followed by 50 cycles at 95°C for
45 seconds, 94°C for 13 seconds, and 53°C for 2 minutes
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then scanned with OpenArray scanner and analyzed using
TaqMan genotyper Software v1.3 (Life Technologies,
Foster City, California). We took a two-step quality
control measure to remove poor quality genotype data.
First, 10% samples were replicated to test the concordance
and reliability of the genotyping result. We excluded
discordant SNPs. This step was followed by excluding
SNPs with a recall rate of < 85% for genotyping; this step
was followed by manual recall for the remaining SNPs.
A total of 40 SNPs passed the two-step quality control
requirement.
Linkage disequilibrium and haplotype analysis
The observed frequencies for all selected SNPs in our
sample were compared with and were in agreement with
the Hardy-Weinberg-Equilibrium. We then evaluated the
linkage disequilibrium structure of the SNPs in our
sample using the Gabriel algorithm (Gabriel et al. 2002).
(HaploView 4.0 Day Lab, Cambridge, MA). This step is
followed by reconstruction of the haplotypes to evaluate
the interaction between SNPs. We conducted haplotype
analysis using haplo-stats Version 1.4.0 (Sinnwell, JP
and Schaid DJ, built in R, version 2.7.1). In this package
the maximum likelihood estimate of a haplotype prob-
ability is calculated using the EM algorithm, and used to
determine possible haplotypes.
Statistical analysis
Distributions of demographic and clinico-pathology vari-
ables between cases and controls were evaluated using
non-parametric and parametric statistics. In developing
the multivariate logistic regression model to determine
the variables that were associated with the risk of PMBC,
we first estimated the individual effect of each variable
and their interactions with the outcome of interest, breast
cancer. Variables with a P-value ≤ 0.10 were considered
as the candidate variables. Interactions between variables
also were tested at P-value ≤ .05. The final model included
five candidate variables (age, smoking status, alcohol con-
sumption status, family history of breast cancer, MetS
and use of hormone replacement therapy (HRT) and the
interaction between MetS and HRT. In our next analysis,
we restricted the reference group to controls with no
history of exposure to HRT or smoking and no clinical
documentation of MetS The final model included age,
family history of breast cancer, HRT, MetS and the inter-
action between HRT and MetS. The estimated risk of
PMBC was not significantly different from our first
approach where all controls were inclusive. Therefore,
we use this reference group to estimate the relative risk
contributions of genetic polymorphism to PMBC in
presence of clinico-demographic risk factors. For each
SNP, testing each SNP individually for its associationwith PMBC, we used the Cockerham genetic model
additive coding scheme and dominant coding scheme
(Cordell 2002). For the additive coding approach, we
assigned the zero, one or two to each SNP genotype
according to the number of copies of minor alleles. For
the dominant coding scheme, we assigned the value
of one for rare homozygozity and zero for the alter-
native homozygotes. The SNPs which showed signifi-
cant association by either coding scheme, were selected
(P-value < 0.1). The final multivariable model was re-
stricted to the dominant coding scheme and was adjusted
by age, family history of breast cancer, HRT, MetS and the
interaction between HRT and MetS. Finally, we evaluated
the risk prediction ability of the final model by plotting
the receiver operating characteristic (ROC) curves and
calculated area under the curve (AUC), which was equiva-
lent to c-statistics, and reported for each model.
Ethics
This study was approved the Institutional Review Board
and is in full compliance with the U.S. Congress Health
Insurance Portability and Accountability Act (HIPAA)
of 1996.
Results
We identified a total of 4,075 women between ages of 40
and 79 years from the MyCode database. (Figure 1) A
total of 309 women were excluded because of the history
of malignancies of organ sites other than breast and/or
auto-immune disorders that required chronic intake of
steroids. We then conducted a search using the ICD-9
coding system for breast cancer (174.x) to identify women
with the diagnosis of breast cancer in this cohort. A total
of 204 women were identified of whom 24 did not meet
the eligibility criteria because their diagnoses pre-dated
January 1, 2001. Therefore, a total of 180 cases and 732
controls contributed to this study. The clinico-demographic
characteristics of the cases and controls are presented in
Table 3. Cases with the mean age of (63.1 ± 9.0) years
were two years younger than controls (65.4 ±7.8). We
did not detect a statistically significant difference in the
mean BMI between cases (32.34 ± 7.89) and controls
(32.16 ± 7.74); however, the proportion of cases (n = 49,
27.22%) who met the three criteria for MetS was signifi-
cantly higher than controls (n = 24, 3.10%) (P-value < .001).
The proportion of cases (n = 64, 64.44%) with medical
documentation of HRT was about 1.8 fold of the
control-patients (n = 280, 36.22%) (P-value < .001). Finally,
twice as many cases (n = 22, 12.22%) as controls (n = 42,
5.43%) had medical documentation of first and/or second
degree family history of breast cancer. Findings from
the multivariate logistic regression of clinico-demographic
characteristics are presented in Table 4. Advanced age













Excluded; Breast Cancer 
Pre 2001, N=24
1:4 Aged Matched Cases and Controls
Figure 1 Selection of cases and controls from the MyCode Biobanking Project.
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(OR = 2.48, 95% CI 1.37-4.47, P-value = .003), HRT (OR=
3.13; 95% CI 2.11-4.64. P-value < .001) and MetS (OR =
12.46, 95% CI 5.62-27.65, P-value < .001) were also asso-
ciated with increased risk of PMBC. Interestingly, our
analysis yielded an interaction between MetS and HRT.
The risk of PMBC was more the 30 fold higher for women
with MetS and exposure to HRT relative to those without
either (OR = 31.90, 95%CI 14.6-69.63, P-value < .001).
Frequency distributions of SNPs of the eight genes
stratified by disease status are presented in Table 5. Fre-
quency differences of one polymorphism in the GHSR
gene (rs2922126), one polymorphism in IL6 gene
(rs1800795) and one polymorphism in the MAP3K1
gene (rs889312) between cases and controls reached the
level of statistical significance. For the gene GHSR
(rs2922126), the proportion of cases (n = 158, 95.15%)
with the dominant allele (T/T and A/T) was higher than
the controls (n = 597, 88.18%). Similarly, prevalence of
the dominant allele (C/C and G/C) of the gene IL6
(rs1800795) was higher for cases (n = 144, 87.8%) com-
pared with the controls (n = 569, 81.4%). Finally, for the
gene MAP3K1 (rs889312), analysis of our data yielded
cases (n = 23, 13.86%) with a higher prevalence of reces-
sive allele (C/C) compared with the controls (n = 41,
5.69%) (Table 5).Results from our final multivariate risk estimation ana-
lysis for SNPs combined with the clinico-demographic
characteristics are presented in Table 6. One SNP
(rs 2922126) in the GHSR showed a protective effect
against PMBC among homozygotes for the minor allele
(A/A) (OR = 0.4, 95% CI 0.18-.89, P-value = .02); while,
homozygosity for the minor allele (C/C) of the SNP
(rs889312) of the gene MAP3K1 was associated with the
risk of PMBC (OR = 2.41, 95% CI 1.25-4.62, P-value = .008).
We did not detected significant interactions between
SNPs or between the SNPs and the clinico-demographic
risk factors. Advanced age continued to be protective
against PMBC (OR= 0.98, 95% CI 0.95-0.99, P-value = .02).
While, family history of breast cancer (OR = 2.22, 95% CI
1.14-4.43. P = .02), HRT (OR = 3.35; 95% CI 2.15-5.21,
P < .001), and MetS (OR = 14.83, 95% CI 5.63-39.08,
P < .001) and interaction between HRT and MetS (OR =
39.38, 95% CI 15.71-98.70, P < .001) remained statistically
significant risk factors for PMBC.
Discussion
Findings from the present study further support results
from previous studies that metabolic syndrome (MetS)
increases the risk of postmenopausal breast cancer
(PMBC) (Bjorge et al. 2010; Kabat et al. 2009; Agnoli
et al. 2010; Esposito et al. 2013). We did not find an
Table 3 Clinico-demographic characteristics of case-patients
and controls
Variable Case-patients Controls P-value
N = 180 (%) N = 773 (%)
Age at entry into the cohort
(years)
63.1 (± 9.00) 65.4 (± 7.80) .001
Body Mass Index (kg/m2) 32.34 (±7.89) 32.16 (± 7.74) .77
Metabolic Syndrome < .001
Yes 49 (27.22) 24 (3.1)
No 131 (72.78) 749 (96.9)
Smoking Status .06
Ever Smoked 47 (26.11) 259 (33.51)
Never Smoked 133 (73.89) 514 (66.49)
Alcohol Consumption .69
Yes 76 (42.22) 314 (40.62)




Yes, ever used 116 (64.44) 280 (36.22)
No, never used 64 (35.56) 493 (63.78)
Family History of Breast
Cancer
.001
(first or second degree)
Yes 22 (12.22) 42 (5.43)
No 158 (87.78) 731 (94.57)
Table 4 Adjusted estimated risk of post-menopausal
breast cancer: Multivariate logistic regression model;
C-statistic = 0.76
Risk factor Cases Controls OR (95% CI)1 P-value





Yes 22 42 1.00
No 158 731 2.48 (1.37-4.47)
Smoking 0.06
Yes 47 259 1.00
No 133 514 0.68 (0.45-1.02)
HRT < 0.001
Yes 116 180 1.00
No 64 493 3.13 (2.11-4.64)
Metabolic Syndrome < 0.001
Yes 49 24 1.00




Yes 33 10 1.0
No 147 763 31.90 (14.6-69.63)
1OR (95% CI): Odds Ratio (95% Confidence Interval).
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the risk of PMBC. In this study, we calculated BMI by
taking the average of height and weight of data collected
across clinical encounters, beginning with the first en-
counter with the system until the date of breast cancer
diagnosis for all cases and their age-matched controls.
Although, BMI adjusts for height, it neither adjusts for
body frame size nor muscle mass. Also, it may be that
insulin resistance rather than excess body weight, al-
though highly correlated, hold the underlying biological
reason for the observed increase risk of PMBC in
women diagnosed with MetS. In this study, we applied
the WHO criterion which recognizes the diagnosis of in-
sulin resistance as the main symptom of MetS (Grundy
et al. 2004). Gunter et al. reported a more than 2-fold in-
crease in the risk of PMBC with fasting serum levels of
insulin which was independent of BMI and other estab-
lished breast cancer risk factors (Gunter et al. 2009).
The complex pathophysiology of hyperinsulinemia, i.e.
increased serum level of insulin-like growth factor-1 (IGF-
1) and leptin and its association with the risk of PMBC
has been evaluated previously and discussed extensively
(Braun et al. 2011; Vatten et al. 2008; Irvin et al. 2005).
IGF-1 and leptin released by visceral adipocytes have
endocrine effects on several organs including breast. Inaddition, it has been suggested IGF-1 and leptin repre-
sent a molecular link between adipose and breast tissue
(Ozhay and Nahta 2008). Adipocytes of stroma of breast
epithelial cells release IGF-1 and leptin which provide
paracrine growth stimulatory effects. It has proposed an
autocrine signaling function as breast cancer are able to
produce and secrete IGF-1 and leptin and express cell sur-
face receptors for both ligands (Ozhay and Nahta 2008).
Also, hyperinsulinemia has been associated with chronic
internal inflammation and oxidative stress which have
been suggested as risk factors for breast and other cancers
(Bondia-Pons et al. 2012; Wiseman and Halliwell 1996).
Our findings yielded an exaggerated risk of PMBC in
women diagnosed with MetS with exposure to HRT. It
is well accepted that HRT increases the risk of hormone
receptor positive breast cancer (Schairer et al. 2000; Ross
et al. 2000). Our findings confirm the report by Gunter
et al. suggesting hyperinsulinemia and serum levels of
estradiol largely explain the association between obesity
and PMBC (Gunter et al. 2009). Similarly, Rosenberg et al.,
have reported of poorer prognostic indicators at the initial
clinical presentation of breast cancer and shorter overall
survival among obese women using HRT when compared
with obese non-users and normal body weight women
(Rosenberg et al. 2009). We propose that the observed
exaggerated risk of PMBC in our study sample most
likely is due to the combination of an increased level of
Table 5 Frequency distribution of SNPs between cases and controls using the dominant coding scheme
Gene,
chromosomal location
SNP Genotype Controls Cases P-value
N (%) N (%)
FTO, 16 q12.2 rs9939609 A/A and A/T 513 (71.35) 122 (72.62) 0.74
T/T 206 (28.65) 46 (27.38)
rs1861868 C/C and C/T 526 (78.39) 123 (76.88) 0.68
T/T 145 (21.61) 37 (23.13)
rs1477196 G/G and A/G 582 (82.32) 135 (82.82) 0.88
A/A 125 (17.68) 28 (17.18)
PTGS2, 1q25.2-25.3 rs2745559 C/C and A/C 632 (95.04) 157 (96.91) 0.31
A/A 33 (4.96) 5 (3.09)
rs689466 T/T and C/T 483 (69.90) 112 (69.14) 0.85
C/C 208 (30.10) 50 (30.86)
rs689470 G/G and A/G 617 (86.90) 153 (90.53) 0.20
A/A 93 (13.10) 16 (9.47)
Rs2206593 G/G and A/G 602 (83.50) 150 (86.71) 0.30
A/A 119 (16.50) 23 (13.29)
rs5277 C/C and C/G 656 (97.33) 155 (98.73) 0.30
G/G 18 (2.67) 2 (1.27)
rs12042763 G/G and G/T 565 (87.73) 134 (86.45) 0.67
T/T 79 (12.27) 21 (13.55)
rs2383529 A/A and A/G 611(94.58) 150 (96.15) 0.42
G/G 35 (5.42) 6 (3.85)
FGGR2, 10q26 rs1219648 A/A and A/G 571 (85.61) 134 (84.28) 0.67
G/G 96 (14.39) 25 (15.72)
rs11200014 G/G and A/G 608 (87.11) 131 (82.39) 0.12
A/A 90 (12.89) 28 (17.61)
rs2981582 G/G and A/G 581 (85.69) 128 (81.53) 0.19
A/A 97 (14.31) 29 (18.47)
GHRL, 3q26.3 rs171336 G/G and G/T 617 (87.64) 148 (90.24) 0.35
T/T 87 (12.36) 16 (9.76)
rs171407 A/A and A/G 554 (80.06) 128 (83.12) 0.39
G/G 138 (19.94) 26 (16.88)
rs35684 A/A and A/G 663 (92.73) 159 (95.21) 0.25
G/G 52 (7.27) 8 (4.79)
rs4684677 T/T and A/T 699 (99.86) 163 (100.00) 0.63
A/A 1 (0.14) 0 (0.00)
rs2075356 T/T and C/T 629 (87.48) 148 (91.93) 0.11
T/T 90 (12.52) 13 (8.07)
rs27647 T/T and C/T 572 (82.18) 142 (87.65) 0.09
C/C 124 (17.82) 20 (12.35)
rs3755777 C/C and C/G 641 (94.40) 152 (94.41) 0.99
G/G 38 (5.60) 9 (5.59)
rs27498 G/G and A/G 604 (87.03) 148 (88.10) 0.71
A/A 90 (12.97) 20 (11.90)
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Table 5 Frequency distribution of SNPs between cases and controls using the dominant coding scheme (Continued)
rs10490815 T/T and C/T 606 (93.09) 140 (92.72) 0.87
C/C 45 (6.91) 11 (7.28)
GHSR, 3q26.2 rs2948694 A/A and A/G 708 (98.33) 163 (98.79) 0.67
G/G 12 (1.67) 2 (1.21)
rs2922126 T/T and A/T 597 (88.18) 158 (95.18) 0.0081
A/A 80 (11.82) 8 (4.82)
IL6, 7p21.0 rs4552807 T/T and A/T 527 (76.16) 128 (75.74) 0.91
A/A 165 (23.84) 41 (24.26)
rs6969502 G/G and A/G 674 (95.33) 158 (94.61) 0.70
A/A 33 (4.67) 9 (5.39)
rs6952003 T/T and A/T 629 (94.44) 147 (94.23) 0.92
A/A 37 (5.56) 9 (5.77)
rs10156056 G/G and C/G 655 (98.05) 153 (98.71) 0.58
C/C 13 (1.95) 2 (1.29)
rs7776857 T/T and G/T 637 (88.23) 150 (92.02) 0.16
G/G 85 (11.77) 13 (7.98)
rs7801617 G/G and A/G 631 (88.50) 158 (93.49) 0.06
A/A 82 (11.50) 11 (6.51)
rs7805828 A/A and A/G 606 (87.57) 133 (83.13) 0.13
G/G 86 (12.43) 27 (16.88)
rs12700386 C/C and C/G 695 (96.80) 161 (96.99) 0.90
G/G 23 (3.20) 5 (3.01)
rs1800795 C/C and G/C 569 (81.40) 144 (87.80) 0.051
G/G 130 (18.60) 20 (12.20)
rs2069840 C/C and C/G 633 (90.56) 151 (89.88) 0.79
G/G 66 (9.44) 17 (10.12)
rs10242595 G/G and A/G 613 (89.75) 143 (91.08) 0.62
A/A 70 (10.25) 14 (8.92)
rs11766273 G/G and A/G 691(98.29) 159 (100.00) 0.097
A/A 12 (1.71) 0 (0.00)
MAP3K1, 5q11.2 rs889312 A/A and A/C 679 (94.31) 143 (86.14) < 0.0011
C/C 41 (5.69) 23 (13.86)
ESR1, 6q25.1 rs2046210 G/G and A/G 573 (83.77) 139 (84.24) 0.88
A/A 111 (16.23) 26 (15.76)
rs12662670 T/T and G/T 631 (92.25) 152 (95.00) 0.23
G/G 53 (7.75) 8 (5.00)
rs3020314 T/T and C/T 564 (80.34) 134 (83.75) 0.32
C/C 138 (19.66) 26 (16.25)
1Genotype distributions between cases and controls were statistically significant.
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to PMBC secondary to MetS. The clinical implication
of this interaction is important, given the high preva-
lence of obesity among the US population, particularly
among African-American and Mexican-American women
(Ford et al. 2002).Our findings suggested polymorphisms of GHSR
(rs2922126) and MAP3K1 (rs889312) were associated
with the risk of PMBC independent of clinico-demographic
risk factors. Our results suggest homozygotes for minor
allele of GHSR (rs2922126) carried a lower risk for PMBC
relative to carriers of major alleles. Dossus et al. reported a
Table 6 Adjusted estimated risk of post-menopausal breast
cancer relative to the reference group, defined as women
with no history of exposure to hormonal replacement
therapy (HRT) and absence of medical documentation of
clinical signs of metabolic syndrome (MetS); C-Statistic = 0.77
Risk factors Cases ControlsW OR (95% CI)1 P-value




T/T and A/T 137 532 1.00
A/A 9 81 .4 (.18-.89)
MAP3K1
(rs889312 )
A/A and A/C 125 573 1.00 .008
C/C 21 40 2.41 (1.25-4.63)




Yes 17 34 2.22 (1.14-4.43)
No 129 579
Risk Factors
Reference Group 37 384 1.00 < 0.001
HRT 70 213 3.35 (2.15-5.21) < 0.001
MetS 12 9 14.83 (5.63-39.08) < 0.001
HRT and MetS 27 7 39.38 (15.71-98.70)
1OR (95% CI) denotes Odds Ratio (95% Confidence Interval).
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carriers of the GHSR (rs2948694) but did not find a sta-
tistically significant association with GHSR (rs2922126)
and risk of breast cancer (Dossus et al. 2010). The dis-
crepancies in findings between these two studies po-
tentially are due to multiple factors. First, our finding
is based on a small sample size of relatively ethnically
homogenous women. Second, women who contributed
to our study on the average were ten years older. Third,
the average BMI for women in our study was about
32 Kg/m2 compared with the average BMI of 26 Kg/m2
women who contributed to the EPIC (Dossus et al. 2010).
Finally, in our study women were categorized by their
MetS diagnostic measures, whereas in the EPIC study
women were classified by their anthropometric mea-
sures and circulating levels of IGF-I. Gherlin and its
receptor primarily have been implicated in growth hor-
mone release, energy balance, food intake and long-term
regulation of body weight. However, recent reports sug-
gest of is complexity and multifarious system such as an
inhibitory effect on pro-inflammatory cytokine expres-
sion (Gahete et al. 2011; Dixit et al. 2004).
We detected polymorphism of MAP3K1 (rs889312) was
associated with an elevated risk of PMBC, independent
of clinico-demographic risk factors. Our findings concurwith previous studies suggesting polymorphism of MAP3KI
(rs889312) was associated with the increased risk of hor-
mone receptor positive breast cancer (Rebbeck et al. 2009;
Easton et al. 2007). Although, we did not assess hormone
receptor status of breast cancer cases in this study, it is
well accepted that prevalence of hormone receptor posi-
tive subtype is the highest in post-menopausal women.
MAP3K1 encodes mitogen-activated protein kinase pro-
tein that is involved in signal transduction pathway, a
highly evolutionarily conserved mechanism of eukaroyotic
cell regulation (Kyriakis and Avruch 2012). The multiple
MAPK pathways present in all eukaroyotic cells enable
cells to coordinate and integrate responses to a spectrum
of stimuli ranging from sex-hormones, growth factors
to inflammation induced cytokines and stress induced
ligands (Kyriakis and Avruch 2012).
The main strength of our study was the availability of
longitudinal body weight and height data. The median
stay with our health care system is 18 years. Therefore,
the availability of long-term data enabled us to estimate
the mean body weight for each study participant which
is a better reflection of the “true” body weight as oppose
to a one-point-in-time measurement or self-reported body
weight. Also, our study benefited from clinically docu-
mented signs and symptoms of MetS and medically docu-
mented use of HRT therapy over the period of stay of
each study participant with the health care system.
Therefore, the likelihood of recall bias was reduced in
this study. Our study had its limitations. First, the rela-
tively small sample size reduced the statistical power to
adequately discern the association between SNPs of genes
and MetS. Also, it prevented us from stratifying women
by their breast cancer subtype. Also, our study sample
was derived from a population relatively homogenous
with respect to its genetic pool and life style risk factors.
Never-the-less, our study further sheds light on the as-
sociate between prolonged MetS and the risk of PMBC.
In summary, findings from our study further confirm
that MetS increases the risk of PMBC and argues in favor
of reducing the exposure to HRT. In addition, our finding
is another independent confirmation that low penetrance
genes involved in the inflammatory pathway, i.e. MAP3KI
gene, may have a plausible causative role in sporadic
breast cancers. Given the fact that genetic constitution-
ality of individuals cannot be changed, at least at the
present level of science and technology, our effort should
be focused on reducing the risk of PMBC through life
style modification.
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